{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:32:35Z","timestamp":1789612355094,"version":"build-2803163510"},"reference-count":231,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["SRG\/2021\/001429"],"award-info":[{"award-number":["SRG\/2021\/001429"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bbcan.2025.189441","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T16:11:38Z","timestamp":1757347898000},"page":"189441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Heparanase as a therapeutic target for mitigating cancer progression"],"prefix":"10.1016","volume":"1880","author":[{"given":"Yogesh","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lokesh","family":"Gambhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2025.189441_bb0005","series-title":"The Cell: A Molecular Approach","author":"Cooper","year":"2000"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189441_bb0010","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1042\/BST20180519","article-title":"Carcinogens and DNA damage","volume":"46","author":"Barnes","year":"2018","journal-title":"Biochem. Soc. Trans."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189441_bb0015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/07357900701208733","article-title":"Carcinogenic food contaminants","volume":"25","author":"Abnet","year":"2007","journal-title":"Cancer Investig."},{"key":"10.1016\/j.bbcan.2025.189441_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.891652","article-title":"Multidrug resistance in Cancer: understanding molecular mechanisms, Immunoprevention and therapeutic approaches","volume":"12","author":"Emran","year":"2022","journal-title":"Front. Oncol."},{"issue":"17","key":"10.1016\/j.bbcan.2025.189441_bb0025","doi-asserted-by":"crossref","first-page":"9451","DOI":"10.3390\/ijms22179451","article-title":"Battling chemoresistance in cancer: root causes and strategies to uproot them","volume":"22","author":"Ramos","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189441_bb0030","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1186\/s12964-024-01857-7","article-title":"Chemoresistance and the tumor microenvironment: the critical role of cell\u2013cell communication","volume":"22","author":"Wilczy\u0144ski","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bbcan.2025.189441_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpt.2025.07.001","article-title":"Chemoresistance: the hidden barrier incancer treatment","author":"Dhiman","year":"2025","journal-title":"Cancer Pathogen. Ther."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189441_bb0040","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","article-title":"Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019","volume":"8","author":"Kocarnik","year":"2022","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb0045","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb0050","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2022","journal-title":"Genes Diseas."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0055","article-title":"Imatinib: a breakthrough of targeted therapy in cancer","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Chemother. Res. Pract."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0060","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0065","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/biomedicines12020297","article-title":"Unraveling the potential of ALK-targeted therapies in non-small cell lung cancer: comprehensive insights and future directions","volume":"12","author":"Parvaresh","year":"2024","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189441_bb0070","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2174\/1568009614666140224155124","article-title":"Heparanase as a target in cancer therapy","volume":"14","author":"Masola","year":"2014","journal-title":"Curr. Cancer Drug Targets"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189441_bb0075","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1172\/JCI200113738","article-title":"Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena","volume":"108","author":"Iozzo","year":"2001","journal-title":"J. Clin. Invest."},{"issue":"20","key":"10.1016\/j.bbcan.2025.189441_bb0080","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.2174\/138161207781039742","article-title":"Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate","volume":"13","author":"Vlodavsky","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bbcan.2025.189441_bb0085","series-title":"Peptides and Proteins as Biomaterials for Tissue Regeneration and Repair","first-page":"29","article-title":"Extracellular matrix constitution and function for tissue regeneration and repair","author":"Caldeira","year":"2018"},{"key":"10.1016\/j.bbcan.2025.189441_bb0090","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3389\/fonc.2019.01316","article-title":"Heparanase: a challenging cancer drug target","volume":"9","author":"Coombe","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0095","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12967-020-02624-1","article-title":"Heparanase and the hallmarks of cancer","volume":"18","author":"Jayatilleke","year":"2020","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb0100","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1042\/bj1251119","article-title":"Degradation of heparin in mouse mastocytoma tissue","volume":"125","author":"\u00d6gren","year":"1971","journal-title":"Biochem. J."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189441_bb0105","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/S0021-9258(19)41657-8","article-title":"Cleavage of macromolecular heparin by an enzyme from mouse mastocytoma","volume":"250","author":"Ogren","year":"1975","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb0110","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/0006-291X(75)90185-0","article-title":"A heparan sulfate-degrading endoglycosidase from rat liver tissue","volume":"67","author":"H\u00f6\u00f6k","year":"1975","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0115","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/0014-5793(76)80287-6","article-title":"Demonstration of a platelet enzyme, degrading heparan sulphate","volume":"64","author":"Wasteson","year":"1976","journal-title":"FEBS Lett."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189441_bb0120","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/0006-291X(76)90848-2","article-title":"Partial purification and characterization of a heparan sulfate specific endoglucuronidase","volume":"73","author":"Klein","year":"1976","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0125","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0006-291X(76)80286-0","article-title":"Evidence for degradation of heparan sulfate by endoglycosidases: glucosamine and hexuronic acid are reducing terminals of intracellular heparan sulfate from human skin fibroblasts","volume":"69","author":"Klein","year":"1976","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189441_bb0130","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/30.3.7061823","article-title":"Metastatic tumor cell attachment and invasion assay utilizing vascular endothelial cell monolayers","volume":"30","author":"Nicolson","year":"1982","journal-title":"J. Histochem. Cytochem."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189441_bb0135","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1016\/S0021-9258(18)34977-9","article-title":"Solubilization and degradation of subendothelial matrix glycoproteins and proteoglycans by metastatic tumor cells","volume":"257","author":"Kramer","year":"1982","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189441_bb0140","first-page":"2704","article-title":"Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis","volume":"43","author":"Vlodavsky","year":"1983","journal-title":"Cancer Res."},{"issue":"4597","key":"10.1016\/j.bbcan.2025.189441_bb0145","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1126\/science.6220468","article-title":"Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines","volume":"220","author":"Nakajima","year":"1983","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.bbcan.2025.189441_bb0150","doi-asserted-by":"crossref","first-page":"11249","DOI":"10.1016\/S0021-9258(18)33749-9","article-title":"Purification and properties of human platelet heparitinase","volume":"257","author":"Oosta","year":"1982","journal-title":"J. Biol. Chem."},{"issue":"Pt 3","key":"10.1016\/j.bbcan.2025.189441_bb0155","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1042\/bj3010917","article-title":"Tumour rejection antigens of the hsp90 family (gp96) closely resemble tumour-associated heparanase enzymes","volume":"301","author":"Graham","year":"1994","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0160","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ijc.2910560224","article-title":"Immunoselection of GRP94\/endoplasmin from a KNRK cell-specific \u03bbGTLL library using antibodies directed against a putative heparanase amino-terminal peptide","volume":"56","author":"de Vouoe","year":"1994","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0165","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1042\/bj3250229","article-title":"A rapid quantitative assay for the detection of mammalian heparanase activity","volume":"325","author":"Freeman","year":"1997","journal-title":"Biochem. J."},{"issue":"34","key":"10.1016\/j.bbcan.2025.189441_bb0170","doi-asserted-by":"crossref","first-page":"24153","DOI":"10.1074\/jbc.274.34.24153","article-title":"Human heparanase. Purification, characterization, cloning, and expression","volume":"274","author":"Toyoshima","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189441_bb0175","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/10518","article-title":"Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis","volume":"5","author":"Vlodavsky","year":"1999","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0180","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/bbrc.1999.0962","article-title":"Cloning and functional expression of a human heparanase gene","volume":"261","author":"Kussie","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189441_bb0185","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/10525","article-title":"Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis","volume":"5","author":"Hulett","year":"1999","journal-title":"Nat. Med."},{"issue":"42","key":"10.1016\/j.bbcan.2025.189441_bb0190","doi-asserted-by":"crossref","first-page":"29587","DOI":"10.1074\/jbc.274.42.29587","article-title":"Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer","volume":"274","author":"Fairbanks","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb0195","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(03)01478-5","article-title":"Heterodimer formation is essential for heparanase enzymatic activity","volume":"308","author":"Levy-Adam","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189441_bb0200","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/nsmb.3136","article-title":"Structural characterization of human heparanase reveals insights into substrate recognition","volume":"22","author":"Wu","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"37","key":"10.1016\/j.bbcan.2025.189441_bb0205","doi-asserted-by":"crossref","first-page":"35152","DOI":"10.1074\/jbc.M300925200","article-title":"Processing of macromolecular heparin by heparanase","volume":"278","author":"Gong","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"26","key":"10.1016\/j.bbcan.2025.189441_bb0210","doi-asserted-by":"crossref","first-page":"18167","DOI":"10.1074\/jbc.M801327200","article-title":"Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment","volume":"283","author":"Abboud-Jarrous","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"14","key":"10.1016\/j.bbcan.2025.189441_bb0215","doi-asserted-by":"crossref","first-page":"10093","DOI":"10.1074\/jbc.C112.444562","article-title":"Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes","volume":"288","author":"Thompson","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/j.bbcan.2025.189441_bb0220","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1158\/0008-5472.CAN-15-0037","article-title":"Heparanase enhances tumor growth and chemoresistance by promoting autophagy","volume":"75","author":"Shteingauz","year":"2015","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.bbcan.2025.189441_bb0225","doi-asserted-by":"crossref","first-page":"6850","DOI":"10.1111\/febs.15776","article-title":"A guide to the composition and functions of the extracellular matrix","volume":"288","author":"Karamanos","year":"2021","journal-title":"FEBS J."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189441_bb0230","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3390\/cells7120236","article-title":"Heparanase: A multitasking protein involved in extracellular matrix (ECM) remodeling and intracellular events","volume":"7","author":"Masola","year":"2018","journal-title":"Cells"},{"issue":"31","key":"10.1016\/j.bbcan.2025.189441_bb0235","doi-asserted-by":"crossref","first-page":"29178","DOI":"10.1074\/jbc.M102462200","article-title":"Expression pattern and secretion of human and chicken heparanase are determined by their signal peptide sequence","volume":"276","author":"Goldshmidt","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189441_bb0240","first-page":"C1184","article-title":"Heparanase induces inflammatory cell recruitment in vivo by promoting adhesion to vascular endothelium","volume":"306","author":"Lever","year":"2014","journal-title":"Am. J. Phys. Cell Phys."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb0245","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0002-9440(10)62321-8","article-title":"Heparanase regulates murine hair growth","volume":"166","author":"Zcharia","year":"2005","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0250","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1096\/fj.04-1970com","article-title":"Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models","volume":"19","author":"Zcharia","year":"2005","journal-title":"FASEB J."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189441_bb0255","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.matbio.2013.02.008","article-title":"Versatile role of heparanase in inflammation","volume":"32","author":"Goldberg","year":"2013","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189441_bb0260","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1089\/wound.2012.0435","article-title":"Innate and adaptive immune responses in wound epithelialization","volume":"3","author":"Strbo","year":"2014","journal-title":"Adv. Wound Care"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189441_bb0265","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/leu.2014.121","article-title":"Heparanase enhances myeloma progression via CXCL10 downregulation","volume":"28","author":"Barash","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189441_bb0270","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1002\/ijc.23898","article-title":"Heparanase induces VEGF C and facilitates tumor lymphangiogenesis","volume":"123","author":"Cohen-Kaplan","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0275","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.tibs.2017.10.007","article-title":"Opposing functions of Heparanase-1 and Heparanase-2 in cancer progression","volume":"43","author":"Vlodavsky","year":"2018","journal-title":"Trends Biochem. Sci."},{"issue":"14","key":"10.1016\/j.bbcan.2025.189441_bb0280","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1039\/C8CS01021H","article-title":"Nanotechnology for angiogenesis: opportunities and challenges","volume":"49","author":"Kargozar","year":"2020","journal-title":"Chem. Soc. Rev."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189441_bb0285","doi-asserted-by":"crossref","first-page":"11364","DOI":"10.18632\/oncotarget.6575","article-title":"Human telomerase reverse transcriptase (hTERT) promotes gastric cancer invasion through cooperating with c-Myc to upregulate heparanase expression","volume":"7","author":"Tang","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189441_bb0290","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/sj.onc.1206201","article-title":"Trans-activation of heparanase promoter by ETS transcription factors","volume":"22","author":"Lu","year":"2003","journal-title":"Oncogene"},{"issue":"28","key":"10.1016\/j.bbcan.2025.189441_bb0295","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1038\/sj.onc.1209425","article-title":"Tumor suppressor p53 regulates heparanase gene expression","volume":"25","author":"Baraz","year":"2006","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189441_bb0300","doi-asserted-by":"crossref","first-page":"8989","DOI":"10.1074\/jbc.M105682200","article-title":"Cloning and characterization of the human Heparanase-1 (HPR1) gene promoter: role of Ga-binding protein and Sp1 in regulating HPR1 Basal promoter activity","volume":"277","author":"Jiang","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"17","key":"10.1016\/j.bbcan.2025.189441_bb0305","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1021\/bi0356552","article-title":"Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression","volume":"43","author":"Chen","year":"2004","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb0310","first-page":"1809","article-title":"Interleukin-17A and heparanase promote angiogenesis and cell proliferation and invasion in cervical cancer","volume":"53","author":"Lv","year":"2018","journal-title":"Int. J. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189441_bb0315","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/09629350120093731","article-title":"Erythromycin and clarithromycin modulation of growth factor-induced expression of heparanase mRNA on human lung cancer cells in vitro","volume":"10","author":"Sasaki","year":"2001","journal-title":"Mediat. Inflamm."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0320","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2011.04.019","article-title":"Mutual enhancement between heparanase and vascular endothelial growth factor: a novel mechanism for melanoma progression","volume":"308","author":"Luan","year":"2011","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0325","first-page":"255","article-title":"Hypoxia activates heparanase expression in an NF-\u03baB dependent manner","volume":"23","author":"Wu","year":"2010","journal-title":"Oncol. Rep."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189441_bb0330","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00125-011-2110-z","article-title":"Reactive oxygen species mediate high glucose-induced heparanase-1 production and heparan sulphate proteoglycan degradation in human and rat endothelial cells: a potential role in the pathogenesis of atherosclerosis","volume":"54","author":"Rao","year":"2011","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189441_bb0335","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.3390\/cancers13122959","article-title":"New heparanase-inhibiting triazolo-thiadiazoles attenuate primary tumor growth and metastasis","volume":"13","author":"Barash","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2025.189441_bb0340","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.matbio.2016.03.006","article-title":"Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype","volume":"55","author":"Ramani","year":"2016","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189441_bb0345","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.exphem.2016.08.006","article-title":"Mechanisms of heparanase inhibitors in cancer therapy","volume":"44","author":"Heyman","year":"2016","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0350","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41523-021-00277-x","article-title":"Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer","volume":"7","author":"Zahavi","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.bbcan.2025.189441_bb0355","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.matbio.2019.11.004","article-title":"Heparanase promotes myeloma stemness and in vivo tumorigenesis","volume":"88","author":"Tripathi","year":"2020","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"key":"10.1016\/j.bbcan.2025.189441_bb0360","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.695858","article-title":"Expression and role of Heparan sulfated proteoglycans in pancreatic cancer","volume":"11","author":"Furini","year":"2021","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189441_bb0365","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41417-024-00754-y","article-title":"Heparanase interacting BCLAF1 to promote the development and drug resistance of ICC through the PERK\/eIF2\u03b1 pathway","volume":"31","author":"Yuan","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0370","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.18632\/oncotarget.6408","article-title":"Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma","volume":"7","author":"Ramani","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2025.189441_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.549412","article-title":"In vitro study of synergic effect of cisplatin and low molecular weight heparin on Oral squamous cell carcinoma","volume":"10","author":"Camacho-Alonso","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189441_bb0380","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13058-024-01906-6","article-title":"The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer","volume":"26","author":"Manouchehri","year":"2024","journal-title":"Breast Cancer Res."},{"issue":"3\u20134","key":"10.1016\/j.bbcan.2025.189441_bb0385","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000175157","article-title":"Non-anticoagulant heparins and inhibition of cancer","volume":"36","author":"Casu","year":"2007","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"10.1016\/j.bbcan.2025.189441_bb0390","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejmech.2016.05.052","article-title":"Recent advances in the discovery of heparanase inhibitors as anti-cancer agents","volume":"121","author":"Jia","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb0395","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1538-7836.2007.02427.x","article-title":"The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials","volume":"5","author":"Lazo-Langner","year":"2007","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189441_bb0400","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/cncr.22892","article-title":"A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications","volume":"110","author":"Kuderer","year":"2007","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189441_bb0405","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/jth.12595","article-title":"The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials","volume":"12","author":"Sanford","year":"2014","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189441_bb0410","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2015.64.0268","article-title":"Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial","volume":"34","author":"Macbeth","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189441_bb0415","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/ph9030038","article-title":"Heparin: past, present, and future","volume":"9","author":"Oduah","year":"2016","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bbcan.2025.189441_bb0420","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.canlet.2017.12.009","article-title":"Supersulfated low-molecular weight heparin synergizes with IGF1R\/IR inhibitor to suppress synovial sarcoma growth and metastases","volume":"415","author":"Cassinelli","year":"2018","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb0425","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/glycob\/cwu119","article-title":"Antitumor properties of a new non-anticoagulant heparin analog from the mollusk Nodipecten nodosus: effect on P-selectin, heparanase, metastasis and cellular recruitment","volume":"25","author":"Gomes","year":"2015","journal-title":"Glycobiology"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189441_bb0430","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1002\/ijc.24239","article-title":"Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor","volume":"124","author":"Lee","year":"2009","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0435","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/polym12010043","article-title":"Redox-responsive heparin\u2013chlorambucil conjugate polymeric prodrug for improved anti-tumor activity","volume":"12","author":"Andrgie","year":"2019","journal-title":"Polymers"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb0440","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1080\/10837450.2019.1711395","article-title":"Novel pH-triggered biocompatible polymeric micelles based on heparin\u2013\u03b1-tocopherol conjugate for intracellular delivery of docetaxel in breast cancer","volume":"25","author":"Emami","year":"2020","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.bbcan.2025.189441_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111831","article-title":"Novel N-acetyl-glycol-split heparin biotin-conjugates endowed with anti-heparanase activity","volume":"186","author":"Esposito","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbcan.2025.189441_bb0450","article-title":"The preparation of pH and GSH dual responsive thiolated heparin\/DOX complex and its application as drug carrier","volume":"230","author":"Chen","year":"2020","journal-title":"Carbohydr. Polym."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0455","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/biom11010046","article-title":"Molecular targeting of VEGF with a Suramin fragment\u2013DOCA conjugate by mimicking the action of low molecular weight heparins","volume":"11","author":"Park","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbcan.2025.189441_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.117490","article-title":"Tumor microenvironment-responsive PEGylated heparin-pyropheophorbide-a nanoconjugates for photodynamic therapy","volume":"255","author":"Wu","year":"2021","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.bbcan.2025.189441_bb0465","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.thromres.2021.01.015","article-title":"Sulfated non-anticoagulant low molecular weight heparin in the prevention of cancer and non-cancer associated thrombosis without compromising hemostasis","volume":"200","author":"Darwish","year":"2021","journal-title":"Thromb. Res."},{"issue":"31","key":"10.1016\/j.bbcan.2025.189441_bb0470","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2203167119","article-title":"Mechanism-based heparanase inhibitors reduce cancer metastasis in vivo","volume":"119","author":"de Boer","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189441_bb0475","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.3390\/biom14091052","article-title":"Synthesis and biological profiling of seven heparin and Heparan Sulphate analogue Trisaccharides","volume":"14","author":"Demeter","year":"2024","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189441_bb0480","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/cells13030211","article-title":"A new synthesized Dicarboxylated oxy-heparin efficiently attenuates tumor growth and metastasis","volume":"13","author":"Li","year":"2024","journal-title":"Cells"},{"issue":"13","key":"10.1016\/j.bbcan.2025.189441_bb0485","doi-asserted-by":"crossref","first-page":"12103","DOI":"10.1074\/jbc.M414217200","article-title":"Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting","volume":"280","author":"Naggi","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2025.189441_bb0490","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.carbpol.2016.09.032","article-title":"Structural features of heparanase-inhibiting non-anticoagulant heparin derivative Roneparstat","volume":"156","author":"Alekseeva","year":"2017","journal-title":"Carbohydr. Polym."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189441_bb0495","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/glycob\/cww003","article-title":"Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase","volume":"26","author":"Pala","year":"2016","journal-title":"Glycobiology"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0500","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1038\/oncsis.2016.5","article-title":"Heparanase-induced shedding of syndecan-1\/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins","volume":"5","author":"Jung","year":"2016","journal-title":"Oncogenesis"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189441_bb0505","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/1078-0432.CCR-10-2476","article-title":"SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase\/syndecan-1 axis","volume":"17","author":"Ritchie","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189441_bb0510","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2017.115","article-title":"NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma","volume":"31","author":"Hao","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0515","first-page":"1071","article-title":"Roneparstat and heparanase inhibition: A new toll for cancer treatment","volume":"5","author":"Barbieri","year":"2017","journal-title":"J. Pharmacol. Clin. Toxicol"},{"issue":"30","key":"10.1016\/j.bbcan.2025.189441_bb0520","doi-asserted-by":"crossref","first-page":"47848","DOI":"10.18632\/oncotarget.10292","article-title":"Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases","volume":"7","author":"Cassinelli","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189441_bb0525","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.3324\/haematol.2017.182865","article-title":"Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy","volume":"103","author":"Galli","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189441_bb0530","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021106","article-title":"M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis","volume":"6","author":"Zhou","year":"2011","journal-title":"PLoS One"},{"issue":"15_Supplement","key":"10.1016\/j.bbcan.2025.189441_bb0535","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1158\/1538-7445.AM2015-5499","article-title":"Necuparanib affects tumor progression and invasion in a 3D co-culture system of pancreatic cancer cells and stellate cells","volume":"75","author":"Krause","year":"2015","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0540","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1535-7163.MCT-18-0417","article-title":"Necuparanib, a multitargeting heparan sulfate mimetic, targets tumor and stromal compartments in pancreatic cancer","volume":"18","author":"MacDonald","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189441_bb0545","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s10637-009-9245-5","article-title":"The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy","volume":"28","author":"Dredge","year":"2010","journal-title":"Investig. New Drugs"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189441_bb0550","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ejca.2015.02.007","article-title":"PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples","volume":"51","author":"Winterhoff","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189441_bb0555","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.18632\/oncotarget.3214","article-title":"The heparan sulfate mimetic PG545 interferes with Wnt\/\u03b2-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine","volume":"6","author":"Jung","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0560","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1172\/JCI76566","article-title":"Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation","volume":"126","author":"Brennan","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2025.189441_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114003","article-title":"Sulfated glycolipid PG545 induces endoplasmic reticulum stress and augments autophagic flux by enhancing anticancer chemotherapy efficacy in endometrial cancer","volume":"178","author":"Hoffmann","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"37","key":"10.1016\/j.bbcan.2025.189441_bb0570","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1038\/s41388-023-02785-5","article-title":"PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction","volume":"42","author":"Ray","year":"2023","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb0575","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00024677-200605040-00002","article-title":"The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy","volume":"5","author":"Abaterusso","year":"2006","journal-title":"Treat. Endocrinol."},{"issue":"Suppl. 1","key":"10.1016\/j.bbcan.2025.189441_bb0580","doi-asserted-by":"crossref","first-page":"i74","DOI":"10.1093\/ndt\/gft389","article-title":"Sulodexide and glycosaminoglycans in the progression of renal disease","volume":"29","author":"Masola","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bbcan.2025.189441_bb0585","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1479-5876-10-213","article-title":"A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition","volume":"10","author":"Masola","year":"2012","journal-title":"J. Transl. Med."},{"issue":"26","key":"10.1016\/j.bbcan.2025.189441_bb0590","doi-asserted-by":"crossref","first-page":"8229","DOI":"10.1021\/jm050618p","article-title":"Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88)","volume":"48","author":"Karoli","year":"2005","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0595","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0008-6215(01)00061-1","article-title":"Large-scale preparation of the oligosaccharide phosphate fraction of Pichia holstii NRRL Y-2448 phosphomannan for use in the manufacture of PI-88","volume":"332","author":"Ferro","year":"2001","journal-title":"Carbohydr. Res."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189441_bb0600","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1517\/13543784.17.11.1769","article-title":"PI-88: a novel inhibitor of angiogenesis","volume":"17","author":"Kudchadkar","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bbcan.2025.189441_bb0605","first-page":"1649","article-title":"Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model","volume":"18","author":"Liang","year":"2012","journal-title":"Mol. Vis."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189441_bb0610","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/sj.leu.2402376","article-title":"Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemias","volume":"16","author":"Iversen","year":"2002","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.bbcan.2025.189441_bb0615","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1038\/sj.onc.1208602","article-title":"A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer","volume":"24","author":"Joyce","year":"2005","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0620","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/glycob\/cwp159","article-title":"Direct detection of HSulf-1 and HSulf-2 activities on extracellular heparan sulfate and their inhibition by PI-88","volume":"20","author":"Hossain","year":"2010","journal-title":"Glycobiology"},{"key":"10.1016\/j.bbcan.2025.189441_bb0625","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx369.008","article-title":"A phase III trial of muparfostat (PI-88) as adjuvant therapy in patients with hepatitis virus related hepatocellular carcinoma (HV-HCC) after resection","volume":"28","author":"Chen","year":"2017","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb0630","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/ph10040078","article-title":"Heparin mimetics: Their therapeutic potential","volume":"10","author":"Mohamed","year":"2017","journal-title":"Pharmaceuticals"},{"issue":"17","key":"10.1016\/j.bbcan.2025.189441_bb0635","doi-asserted-by":"crossref","first-page":"8779","DOI":"10.1158\/0008-5472.CAN-06-1382","article-title":"Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis","volume":"66","author":"Zhao","year":"2006","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189441_bb0640","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/aps.2009.97","article-title":"Marine-derived oligosaccharide sulfate (JG3) suppresses heparanase-driven cell adhesion events in heparanase over-expressing CHO-K1 cells","volume":"30","author":"Li","year":"2009","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189441_bb0645","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/aps.2010.13","article-title":"Oligomannurarate sulfate blocks tumor growth by inhibiting NF-\u03baB activation","volume":"31","author":"Zhang","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0650","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/ijc.26021","article-title":"Oligomannurarate sulfate sensitizes cancer cells to doxorubicin by inhibiting atypical activation of NF-\u03baB via targeting of Mre11","volume":"130","author":"Zhang","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0655","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4161\/cbt.10.1.12167","article-title":"Oligomannurarate sulfate, a novel antimitotic agent, exerts anti-cancer activity by binding to tubulin on novel site","volume":"10","author":"Miao","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bbcan.2025.189441_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105527","article-title":"Oligosaccharides from fucosylated glycosaminoglycan prevent breast cancer metastasis in mice by inhibiting heparanase activity and angiogenesis","volume":"166","author":"Zhou","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb0665","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/1078-0432.CCR-08-1270","article-title":"Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias","volume":"15","author":"Mitsiades","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 1","key":"10.1016\/j.bbcan.2025.189441_bb0670","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000215336","article-title":"Pharmacokinetics of defibrotide in healthy volunteers","volume":"16","author":"Noseda","year":"1986","journal-title":"Pathophysiol. Haemost. Thromb."},{"issue":"1\u20132","key":"10.1016\/j.bbcan.2025.189441_bb0675","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2013.05.001","article-title":"Defibrotide: properties and clinical use of an old\/new drug","volume":"59","author":"Pescador","year":"2013","journal-title":"Vasc. Pharmacol."},{"issue":"13","key":"10.1016\/j.bbcan.2025.189441_bb0680","first-page":"1719","article-title":"What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance","volume":"127","author":"Palomo","year":"2016","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"14","key":"10.1016\/j.bbcan.2025.189441_bb0685","doi-asserted-by":"crossref","first-page":"8031","DOI":"10.1111\/jcmm.15434","article-title":"Defibrotide inhibits donor leucocyte-endothelial interactions and protects against acute graft-versus-host disease","volume":"24","author":"Garc\u00eda-Bernal","year":"2020","journal-title":"J. Cell. Mol. Med."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189441_bb0690","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1038\/s41409-021-01383-x","article-title":"The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae","volume":"56","author":"Richardson","year":"2021","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0695","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1172\/JCI118810","article-title":"Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides","volume":"98","author":"Wang","year":"1996","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189441_bb0700","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.0.CO;2-L","article-title":"Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides","volume":"83","author":"Miao","year":"1999","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189441_bb0705","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037938","article-title":"Development of novel single-stranded nucleic acid aptamers against the pro-angiogenic and metastatic enzyme heparanase (HPSE1)","volume":"7","author":"Simmons","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189441_bb0710","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096846","article-title":"Anti-heparanase aptamers as potential diagnostic and therapeutic agents for oral cancer","volume":"9","author":"Simmons","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189441_bb0715","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/cbic.200800805","article-title":"Molecular assembly of an aptamer\u2013drug conjugate for targeted drug delivery to tumor cells","volume":"10","author":"Huang","year":"2009","journal-title":"ChemBioChem"},{"issue":"31","key":"10.1016\/j.bbcan.2025.189441_bb0720","doi-asserted-by":"crossref","first-page":"8889","DOI":"10.1002\/anie.201602702","article-title":"N-Heterocyclic Carbene\u2013Gold (I) complexes conjugated to a Leukemia-Specific DNA Aptamer for targeted drug delivery","volume":"55","author":"Niu","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0725","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41467-017-01565-6","article-title":"A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer","volume":"8","author":"Li","year":"2017","journal-title":"Nat. Commun."},{"issue":"34","key":"10.1016\/j.bbcan.2025.189441_bb0730","doi-asserted-by":"crossref","first-page":"11661","DOI":"10.1002\/anie.201903807","article-title":"Molecular engineering-based aptamer\u2013drug conjugates with accurate tunability of drug ratios for drug combination targeted cancer therapy","volume":"58","author":"Zhou","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189441_bb0735","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1021\/jacs.9b12409","article-title":"Conjugating aptamer and mitomycin C with reductant-responsive linker leading to synergistically enhanced anticancer effect","volume":"142","author":"Yang","year":"2020","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189441_bb0740","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1021\/jacs.9b10510","article-title":"Molecularly engineering triptolide with aptamers for high specificity and cytotoxicity for triple-negative breast cancer","volume":"142","author":"He","year":"2020","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0745","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41392-021-00671-8","article-title":"A new paradigm for artesunate anticancer function: considerably enhancing the cytotoxicity via conjugating artesunate with aptamer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189441_bb0750","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1182\/blood-2005-08-3301","article-title":"Role of endothelial heparanase in delayed-type hypersensitivity","volume":"107","author":"Edovitsky","year":"2006","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bbcan.2025.189441_bb0755","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/jnci\/djh230","article-title":"Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis","volume":"96","author":"Edovitsky","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0760","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1477-7819-12-85","article-title":"Gene silencing of heparanase results in suppression of invasion and migration of hepatoma cells","volume":"12","author":"Dong","year":"2014","journal-title":"World J. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189441_bb0765","first-page":"1601","article-title":"Downregulation of heparanase by RNA interference inhibits invasion and tumorigenesis of hepatocellular cancer cells in vitro and in vivo","volume":"40","author":"Xiong","year":"2012","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0770","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031379","article-title":"Small RNAs targeting transcription start site induce heparanase silencing through interference with transcription initiation in human cancer cells","volume":"7","author":"Jiang","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189441_bb0775","first-page":"233","article-title":"Evaluation of the antitumor efficacy of RNAi-mediated inhibition of CDC20 and Heparanase in an Orthotopic liver tumor model","volume":"30","author":"Liu","year":"2015","journal-title":"Cancer Biother. Radiopharm."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189441_bb0780","article-title":"An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2025.189441_bb0785","first-page":"4371","article-title":"Inhibition of choriocarcinoma by Fe3O4-dextran-anti-\u03b2-human chorionic gonadotropin nanoparticles containing antisense oligodeoxynucleotide of heparanase","author":"Huining","year":"2013","journal-title":"Int. J. Nanomedicine"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189441_bb0790","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jb\/mvj061","article-title":"Novel heparanase-inhibiting antibody reduces neointima formation","volume":"139","author":"Myler","year":"2006","journal-title":"J. Biochem."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189441_bb0795","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00262-008-0651-x","article-title":"Screening and identification of novel B cell epitopes in human heparanase and their anti-invasion property for hepatocellular carcinoma","volume":"58","author":"Yang","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189441_bb0800","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051494","article-title":"Clinical significance of heparanase splice variant (t5) in renal cell carcinoma: evaluation by a novel t5-specific monoclonal antibody","volume":"7","author":"Barash","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189441_bb0805","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1073\/pnas.1519453113","article-title":"Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis","volume":"113","author":"Weissmann","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189441_bb0810","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2174\/138920308785915227","article-title":"Branched peptides as therapeutics","volume":"9","author":"Pini","year":"2008","journal-title":"Curr. Protein Pept. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0815","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.vaccine.2008.10.025","article-title":"Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan","volume":"27","author":"Iriemenam","year":"2009","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189441_bb0820","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1158\/1940-6207.CAPR-11-0083","article-title":"Multiple antigenic peptides of human heparanase elicit a much more potent immune response against tumors","volume":"4","author":"Wang","year":"2011","journal-title":"Cancer Prev. Res. (Phila.)"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189441_bb0825","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.3892\/or.2013.2347","article-title":"Peptide FLNPDVLDI of heparanase is a novel HLA-A2-restricted CTL epitope and elicits potent immunological antitumor effects in vitro with an 8-branched design","volume":"29","author":"Zhang","year":"2013","journal-title":"Oncol. Rep."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189441_bb0830","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.vaccine.2012.01.002","article-title":"Heparanase DNA vaccine delivered by electroporation induces humoral immunity and cytoimmunity in animal models","volume":"30","author":"Fu","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0835","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/cas.12308","article-title":"In vitro and ex vivo evaluation of a multi-epitope heparinase vaccine for various malignancies","volume":"105","author":"Tang","year":"2014","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189441_bb0840","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4155\/fmc-2016-0012","article-title":"Heparanase: a rainbow pharmacological target associated with multiple pathologies including rare diseases","volume":"8","author":"Rivara","year":"2016","journal-title":"Future Med. Chem."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189441_bb0845","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/0960-0760(90)90439-R","article-title":"Suramin, a novel antitumor compound","volume":"37","author":"La Rocca","year":"1990","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb0850","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1200\/JCO.1989.7.4.499","article-title":"Suramin: an anticancer drug with a unique mechanism of action","volume":"7","author":"Stein","year":"1989","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.bbcan.2025.189441_bb0855","first-page":"4957","article-title":"Antiproliferative and angiostatic activity of suramin analogues","volume":"55","author":"Firsching","year":"1995","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0860","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ijc.10930","article-title":"Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues","volume":"104","author":"Marchetti","year":"2003","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0865","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/bjc.1992.272","article-title":"Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity","volume":"66","author":"Pesenti","year":"1992","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189441_bb0870","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12935-015-0196-y","article-title":"Suramin inhibits cell proliferation in ovarian and cervical cancer by downregulating heparanase expression","volume":"15","author":"Li","year":"2015","journal-title":"Cancer Cell Int."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0875","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.canlet.2010.05.016","article-title":"A small oxazine compound as an anti-tumor agent: A novel pyranoside mimetic that binds to TNF-\u03b1, HB-EGF and VEGF","volume":"297","author":"Nevin","year":"2010","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0880","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.canlet.2010.05.016","article-title":"A small oxazine compound as an anti-tumor agent: a novel pyranoside mimetic that binds to VEGF, HB-EGF, and TNF-\u03b1","volume":"297","author":"Murugan","year":"2010","journal-title":"Cancer Lett."},{"issue":"24","key":"10.1016\/j.bbcan.2025.189441_bb0885","doi-asserted-by":"crossref","first-page":"36154","DOI":"10.18632\/oncotarget.8959","article-title":"Novel 1, 3-N, O-Spiroheterocyclic compounds inhibit heparanase activity and enhance nedaplatin-induced cytotoxicity in cervical cancer cells","volume":"7","author":"Song","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189441_bb0890","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1016\/j.bmcl.2004.03.086","article-title":"2,3-Dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid derivatives: A novel class of small molecule heparanase inhibitors","volume":"14","author":"Courtney","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189441_bb0895","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.bmcl.2005.03.014","article-title":"Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor","volume":"15","author":"Courtney","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0900","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.bmcl.2005.09.070","article-title":"N-(4-{[4-(1H-Benzoimidazol-2-yl)-arylamino]-methyl}-phenyl)-benzamide derivatives as small molecule heparanase inhibitors","volume":"16","author":"Xu","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0905","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.bmcl.2005.09.069","article-title":"1-[4-(1H-benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea derivatives as small molecule heparanase inhibitors","volume":"16","author":"Pan","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0910","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3892\/ol.2024.14217","article-title":"Heparanase inhibitor OGT 2115 induces prostate cancer cell apoptosis via the downregulation of MCL-1","volume":"27","author":"Li","year":"2024","journal-title":"Oncol. Lett."},{"issue":"14","key":"10.1016\/j.bbcan.2025.189441_bb0915","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3390\/cells12141891","article-title":"Role of a novel Heparanase inhibitor on the balance between apoptosis and autophagy in U87 human glioblastoma cells","volume":"12","author":"Manganelli","year":"2023","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189441_bb0920","doi-asserted-by":"crossref","first-page":"12058","DOI":"10.1021\/acs.jmedchem.5c00937","article-title":"Design of Paromomycin and Neomycin as sulfated and hydrophobic Glycans to target Heparanase-driven tumor progression and metastasis","volume":"68","author":"Abdulsalam","year":"2025","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.bbcan.2025.189441_bb0925","doi-asserted-by":"crossref","first-page":"8544","DOI":"10.1039\/D5NR00079C","article-title":"Poly[(N-acryloyl glycine)-co-(acrylamide)]-induced cell growth inhibition in heparanase-driven malignancies","volume":"17","author":"Wasnik","year":"2025","journal-title":"Nanoscale"},{"issue":"29","key":"10.1016\/j.bbcan.2025.189441_bb0930","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202470175","article-title":"A novel drug candidate for sepsis targeting heparanase by inhibiting cytokine storm","volume":"11","author":"Wang","year":"2024","journal-title":"Adv. Sci."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0935","doi-asserted-by":"crossref","first-page":"136","DOI":"10.7164\/antibiotics.57.136","article-title":"Exploitation of heparanase inhibitors from microbial metabolites using an efficient visual screening system","volume":"57","author":"Ishida","year":"2004","journal-title":"J. Antibiot."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb0940","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/0014-5793(95)00953-7","article-title":"RK-682, a potent inhibitor of tyrosine phosphatase, arrested the mammalian cell cycle progression at G1phase","volume":"372","author":"Hamaguchi","year":"1995","journal-title":"FEBS Lett."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189441_bb0945","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1535-7163.1069.3.9","article-title":"Structure-based design of a selective heparanase inhibitor as an antimetastatic agent","volume":"3","author":"Ishida","year":"2004","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189441_bb0950","doi-asserted-by":"crossref","first-page":"357","DOI":"10.7164\/antibiotics.48.357","article-title":"Trachyspic acid, a new metabolite produced by Talaromyces trachyspermus, that inhibits tumor cell heparanase: taxonomy of the producing strain, fermentation, isolation, structural elucidation, and biological activity","volume":"48","author":"Shiozawa","year":"1995","journal-title":"J. Antibiot."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189441_bb0955","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ja.2016.167","article-title":"Trachyspic acid 19-butyl ester, a new inhibitor of Plk1 polo box domain-dependent recognition from uncharacterized fungus RKGS-F2684","volume":"70","author":"Nogawa","year":"2017","journal-title":"J. Antibiot."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189441_bb0960","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/jid.2008.358","article-title":"PS3, a semisynthetic \u03b2-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L- and P-selectin functions","volume":"129","author":"Alban","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bbcan.2025.189441_bb0965","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpba.2014.02.021","article-title":"Testing of potential glycan-based heparanase inhibitors in a fluorescence activity assay using either bacterial heparinase II or human heparanase","volume":"95","author":"Schoenfeld","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb0970","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/glycob\/cwn151","article-title":"Pharmacological profiles of animal-and nonanimal-derived sulfated polysaccharides\u2013comparison of unfractionated heparin, the semisynthetic glucan sulfate PS3, and the sulfated polysaccharide fraction isolated from Delesseria sanguinea","volume":"19","author":"Groth","year":"2009","journal-title":"Glycobiology"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb0975","doi-asserted-by":"crossref","first-page":"211","DOI":"10.7164\/antibiotics.53.211","article-title":"CRM646-A and -B, novel fungal metabolites that inhibit heparanase","volume":"53","author":"Ko","year":"2000","journal-title":"J. Antibiot."},{"key":"10.1016\/j.bbcan.2025.189441_bb0980","series-title":"U.S. Patent No. 7,060,714","author":"Ahn","year":"2006"},{"issue":"22","key":"10.1016\/j.bbcan.2025.189441_bb0985","doi-asserted-by":"crossref","first-page":"8884","DOI":"10.1021\/jo051384k","article-title":"Total synthesis of CRM646-A and -B, two fungal glucuronides with potent heparinase inhibition activities","volume":"70","author":"Wang","year":"2005","journal-title":"J. Organomet. Chem."},{"key":"10.1016\/j.bbcan.2025.189441_bb0990","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF00689050","article-title":"Selective inhibition of cell proliferation and DNA synthesis by the polysulphated carbohydrate \u03b9-carrageenan","volume":"36","author":"Hoffman","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb0995","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ijc.2910400414","article-title":"Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour-cell-derived heparanases","volume":"40","author":"Parish","year":"1987","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189441_bb1000","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1091\/mbc.1.11.833","article-title":"Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix","volume":"1","author":"Ishai-Michaeli","year":"1990","journal-title":"Cell. Regul."},{"key":"10.1016\/j.bbcan.2025.189441_bb1005","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.carbpol.2015.02.069","article-title":"Modulation of the binding of basic fibroblast growth factor and heparanase activity by purified \u03bb-carrageenan oligosaccharides","volume":"125","author":"Niu","year":"2015","journal-title":"Carbohydr. Polym."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189441_bb1010","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/md15050134","article-title":"Assessment of Heparanase-mediated angiogenesis using microvascular endothelial cells: identification of \u03bb-carrageenan derivative as a potent anti Angiogenic agent","volume":"15","author":"Poupard","year":"2017","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.bbcan.2025.189441_bb1015","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.carbpol.2017.02.040","article-title":"Production of heparin and \u03bb-carrageenan anti-heparanase derivatives using a combination of physicochemical depolymerization and glycol splitting","volume":"166","author":"Poupard","year":"2017","journal-title":"Carbohydr. Polym."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb1020","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3892\/mmr.2017.6638","article-title":"Elemene inhibits the migration and invasion of 4T1 murine breast cancer cells via heparanase","volume":"16","author":"Zhang","year":"2017","journal-title":"Mol. Med. Rep."},{"issue":"26\u201329","key":"10.1016\/j.bbcan.2025.189441_bb1025","first-page":"32","article-title":"Study on effect of quercetin on tumor growth of cervical carcinoma in nude mouse model and its relationship with expression of heparanase","volume":"35","author":"Wei","year":"2015","journal-title":"Zhongguo Shenghua Yaowu Zazhi"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189441_bb1030","first-page":"198","volume":"48","author":"Zhang","year":"2013","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb1035","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202200619","article-title":"Synthesis of Uronic acid 1-Azasugars as putative inhibitors of \u03b1-Iduronidase, \u03b2-Glucuronidase and Heparanase","volume":"24","author":"Doherty","year":"2023","journal-title":"ChemBioChem"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189441_bb1040","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1634\/theoncologist.2017-0472","article-title":"Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: phase I results","volume":"22","author":"O\u2019Reilly","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2025.189441_bb1045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2020.03.005","article-title":"Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreatic ductal adenocarcinoma","volume":"132","author":"O\u2019Reilly","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189441_bb1050","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41416-018-0006-0","article-title":"A phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours","volume":"118","author":"Dredge","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189441_bb1055","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s13346-020-00744-1","article-title":"Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation","volume":"10","author":"Taha","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb1060","doi-asserted-by":"crossref","DOI":"10.1017\/cts.2020.523","article-title":"A framework for clinical and translational research in the era of rigor and reproducibility","volume":"5","author":"Wichman","year":"2020","journal-title":"J. Clin. Transl. Sci."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb1065","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3390\/s22041592","article-title":"Determination of drugs in clinical trials: current status and outlook","volume":"22","author":"Tavana","year":"2022","journal-title":"Sensors (Basel, Switzerland)"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189441_bb1070","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.3390\/molecules23112915","article-title":"Heparan sulfate mimetics in Cancer therapy: the challenge to define structural determinants and the relevance of targets for optimal activity","volume":"23","author":"Lanzi","year":"2018","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"32","key":"10.1016\/j.bbcan.2025.189441_bb1075","doi-asserted-by":"crossref","first-page":"11384","DOI":"10.3748\/wjg.v20.i32.11384","article-title":"Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence","volume":"20","author":"Liu","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189441_bb1080","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/bjc.2011.11","article-title":"PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models","volume":"104","author":"Dredge","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189441_bb1085","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.isci.2019.04.034","article-title":"Targeting Heparanase in cancer: inhibition by synthetic, chemically modified, and natural compounds","volume":"15","author":"Mohan","year":"2019","journal-title":"iScience"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189441_bb1090","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/jcp.30995","article-title":"Potential roles of heparanase in cancer therapy: current trends and future direction","volume":"238","author":"Yang","year":"2023","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb1095","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12672-025-01985-7","article-title":"Multifaceted role of heparin in oncology: from anticoagulation to anticancer mechanisms and clinical implications","volume":"16","author":"Koirala","year":"2025","journal-title":"Discov. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189441_bb1100","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189441_bb1105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3892\/ijo.2022.5315","article-title":"Downregulation of heparanase by RNA interference inhibits invasion and tumorigenesis of hepatocellular cancer cells in vitro and in vivo","volume":"60","author":"Xiong","year":"2022","journal-title":"Int. J. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189441_bb1110","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3892\/or.2014.3679","article-title":"Multiple antigenic polypeptide composed of heparanase B-cell epitopes shrinks human hepatocellular carcinoma in mice","volume":"33","author":"Zhang","year":"2015","journal-title":"Oncol. Rep."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189441_bb1115","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1310\/hpj5110-847","article-title":"Defibrotide","volume":"51","author":"Baker","year":"2016","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.bbcan.2025.189441_bb1120","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review","volume":"11","author":"Fogel","year":"2018","journal-title":"Contemp. Clini. Trials Commun."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189441_bb1125","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1124\/dmd.120.000054","article-title":"A new data repository for pharmacokinetic natural product-drug interactions: from chemical characterization to clinical studies","volume":"48","author":"Birer-Williams","year":"2020","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb1130","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1124\/pharmrev.120.000106","article-title":"Modeling pharmacokinetic natural product-drug interactions for decision-making: A NaPDI center recommended approach","volume":"73","author":"Cox","year":"2021","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb1135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0707182","article-title":"Heparanase: a target for drug discovery in cancer and inflammation","volume":"151","author":"McKenzie","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189441_bb1140","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/molecules23020346","article-title":"Suramin-induced neurotoxicity: preclinical models and neuroprotective strategies","volume":"23","author":"von der Ahe","year":"2018","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189441_bb1145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1096\/fj.201902143R","article-title":"Improving natural product research translation: from source to clinical trial","volume":"34","author":"Sorkin","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.bbcan.2025.189441_bb1150","series-title":"Design and Synthesis of Aminoglycoside-Based Heparan Sulfate Mimetics for Structure-Activity Relationship Studies of Heparan-Binding Proteins","author":"Wakpal","year":"2024"},{"issue":"20","key":"10.1016\/j.bbcan.2025.189441_bb1155","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.3390\/molecules27207116","article-title":"Heparin-superparamagnetic Iron oxide nanoparticles for Theranostic applications","volume":"27","author":"Massironi","year":"2022","journal-title":"Molecules (Basel, Switzerland)"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25001830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25001830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T21:25:46Z","timestamp":1758144346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25001830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":231,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0304419X25001830"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189441","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heparanase as a therapeutic target for mitigating cancer progression","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189441"}}